BPL1 postbiotic (Lactobacillus fermentate 500 mg daily) reduces visceral fat 15-20% and insulin resistance 15% by enhancing barrier function (reducing LPS 30%), promoting SCFA production (GPR43 signaling), and shifting microbiota toward butyrate-producers; effects persist post-supplementation.
Sigue leyendo
Postbiotics (Lactobacillus fermentates) show superior stability and bioavailability (>90%) compared to probiotics (<1% survival); BPL1 reduces visceral fat 15-20%, improves insulin sensitivity +12%, and sustains effects post-supplementation via SCFA/bacteriocin signaling.
Sigue leyendo